18F, 64Cu, and68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer

Bioconjugate Chemistry

Volumn 20, Issue 5, 2009, Pages 1016-1025

  Liu, Zhaofei ^a,b   Yan, Yongjun ^a   Liu, Shuanglong ^a   Wang, Fan ^b   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BIOMOLECULES; CELLS; CYTOLOGY; DISEASES; MEDICAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SYNTHESIS (CHEMICAL); TUMORS;

ARG GLY ASPS; BREAST CANCER; BREAST CANCER CELLS; HETERODIMERS; INTEGRINS; PEPTIDE RECEPTOR; PET IMAGING; SYNTHESISED; TUMOR IMAGING; TUMOR UPTAKE;

PEPTIDES;

ARGINYLGLYCYLASPARTIC ACID; BOMBESIN; COPPER 64; COPPER 64 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID BOMBESIN; FLUORINE 18; FLUORINE 18 N SUCCINIMIDYL 4 FLUOROBENZOATE 11 AMINO 3,6,9 TRIOXAUNDECANOIC ACID ARGINYLGLYCYLASPARTIC ACID BOMBESIN; GALLIUM 68; GALLIUM 68 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID ARGINYLGLYCYLASPARTIC ACID BOMBESIN; GASTRIN RELEASING PEPTIDE RECEPTOR; HETERODIMER; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; BOMBESIN RECEPTOR; COPPER; FLUORINE; GALLIUM; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER MODEL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG RETENTION; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LIVER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; TUMOR CELL; ANIMAL; BLOOD; BREAST TUMOR; CHEMISTRY; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; RADIOCHEMISTRY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; BOMBESIN; BREAST NEOPLASMS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; FLUORINE RADIOISOTOPES; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RADIOCHEMISTRY; RECEPTORS, BOMBESIN;

EID: 66149176919     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc9000245     Document Type: Article

References (52)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. (2001) Cancer statistics, 2001. Ca - Cancer J. Clin. 51, 15-36. (Pubitemid 32166444)
2. Veronesi, U., Boyle, P., Goldhirsch, A., Orecchia, R., and Viale, G. (2005) Breast cancer. Lancet 365, 1727-1741. (Pubitemid 40719108)
3. Weigelt, B., Peterse, J. L., and van't Veer, L. J. (2005) Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602.
4. Cornelio, D. B., Roesler, R., and Schwartsmann, G. (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann. Oncol. 18, 1457-1466. (Pubitemid 47365477)
5. Smith, C. J., Volkert, W. A., and Hoffman, T. J. (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol. 32, 733-740. (Pubitemid 41502979)
6. 3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjugate Chem. 19, 2432-2439.
7. 3]-bombesin: biokinetics and dosimetry in women. Nucl. Med. Commun. 29, 741-747.
8. 2 structural paradigm in a prostate cancer model. Bioconjugate Chem. 19, 1803-1812.
9. Van de Wiele, C., Phonteyne, P., Pauwels, P., Goethals, I., Van den Broecke, R., Cocquyt, V., and Dierckx, R. A. (2008) Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J. Nucl. Med. 49, 260-264.
10. 3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45, 1390-1397.
11. Zhang, X., Cai, W., Cao, F., Schreibmann, E., Wu, Y., Wu, J. C., Xing, L., and Chen, X. (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J. Nucl. Med. 47, 492-501. (Pubitemid 46768492)
12. 18F-FDG. J. Nucl. Med. 48, 1245-1250.
13. 68Ga- labeled bombesin(6-14) analog. J. Nucl. Med. 46, 691-699.
14. 177Lu-AMBA. Eur. J. Nucl. Med. Mol. Imaging 34, 95-100.
15. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med. 47, 1144-1152.
16. Zhang, H., Chen, J., Waldherr, C., Hinni, K., Waser, B., Reubi, J. C., and Maecke, H. R. (2004) Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 64, 6707-6715. (Pubitemid 39302601)
17. Cai, W., Shin, D. W., Chen, K., Gheysens, O., Cao, Q., Wang, S. X., Gambhir, S. S., and Chen, X. (2006) Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6, 669-676.
18. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol. 33, 371-380.
19. Scopinaro, F., Varvarigou, A. D., Ussof, W., De Vincentis, G., Sourlingas, T. G., Evangelatos, G. P., Datsteris, J., and Archimandritis, S. C. (2002) Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother. Radiopharm. 17, 327-335.
20. Parry, J. J., Andrews, R., and Rogers, B. E. (2007) MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res. Treat. 101, 175-183 (Pubitemid 46115423)
21. Hood, J. D., and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100. (Pubitemid 37328796)
22. Ruoslahti, E. (2002) Specialization of tumour vasculature. Nat. Rev. Cancer 2, 83-90. (Pubitemid 37328795)
23. Brooks, P. C., Clark, R. A., and Cheresh, D. A. (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264, 569-571. (Pubitemid 24185862)
24. Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687. (Pubitemid 35283958)
25. Chen, X., Park, R., Shahinian, A. H., Tohme, M., Khankaldyyan, V., Bozorgzadeh, M. H., Bading, J. R., Moats, R., Laug, W. E., and Conti, P. S. (2004) 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 31, 179-189. (Pubitemid 38315112)
26. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
27. 18F-FRGD2. J. Nucl. Med. 47, 113-121.
28. 18F-Galacto-RGD PET. J. Nucl. Med. 49, 255-259.
29. 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 35, 1507-1515.
30. Cai, W., Niu, G., and Chen, X. (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 14, 2943-2973.
31. Cai, W., and Chen, X. (2008) Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49 (Suppl. 2), 113S-128S.
32. Chen, X. (2006) Multimodality imaging of tumor integrin αvβ3 expression. Mini-Rev. Med. Chem. 6, 227-234.
33. 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49, 879-886.
34. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med. 49, 453-461.
35. 3-Glu-RGD-BBN. J. Med. Chem. 52, 425-432.
36. 18F-fluorobenzamido)ethyl] maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αvβ3 integrin expression. J. Nucl. Med. 47, 1172-1180.
37. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression. Eur. J. Nucl. Med. Mol. Imaging 35, 1100-1108.
38. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J. Nucl. Med. 48, 1162-1171.
39. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19.
40. 18F- FPRGD2): synthesis and microPET imaging of αvβ3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 34, 1823-1831.
41. Strande, V., Canelle, L., Tastet, C., Burlet-Schiltz, O., Monsarrat, B., and, and Hondermarck, H. (2009) The proteome of the human breast cancer cell line MDA-MB-231: analysis by LTQ-Orbitrap mass spectrometry. Proteomics: Clin. Appl. 3, 41-50.
42. Cassoni, P., Papotti, M., Ghe, C., Catapano, F., Sapino, A., Graziani, A., Deghenghi, R., Reissmann, T., Ghigo, E., and Muccioli, G. (2001) Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 86, 1738-1745. (Pubitemid 32374931)
43. Bajo, A. M., Schally, A. V., Krupa, M., Hebert, F., Groot, K., and Szepeshazi, K. (2002) Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc. Natl. Acad. Sci. U.S.A. 99, 3836-3841. (Pubitemid 34252192)
44. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., and Meltzer, P. S. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968. (Pubitemid 27366683)
45. Brandi, G., Paiardini, M., Cervasi, B., Fiorucci, C., Filippone, P., De Marco, C., Zaffaroni, N., and Magnani, M. (2003) A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 63, 4028-4036. (Pubitemid 36917923)
46. 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 66, 9673-9681.
47. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359.
48. 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J. Nucl. Med. 49, 1819-1827.
49. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U.S.A. 104, 12462-12467.
50. Boswell, C. A., Sun, X., Niu, W., Weisman, G. R., Wong, E. H., Rheingold, A. L., and Anderson, C. J. (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med. Chem. 47, 1465-1474. (Pubitemid 38327472)
51. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med. 48, 1327-1337.
52. Clarke, E., and Martell, A. E. (1991) Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N′,N″-triazacyclononanetriacetic acid. Inorg. Chim. Acta 181, 273-280.